Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

Key Inclusion Criteria: * Established diagnosis of hypertrophic cardiomyopathy defined by standard criteria as a maximal left ventricular wall thickness ≥ 15 mm at initial diagnosis * Exertional symptoms including at least one of the following: * New York Heart Association (NYHA) Class ≥ II dyspnea * Canadian Cardiovascular Society (CCS) Class ≥ II angina * Screening (baseline) peak VO2 \< 80% of predicted for age, sex, and weight * Ability to perform an upright treadmill cardiopulmonary exercise test (CPET) Key Exclusion Criteria: * Known aortic valve stenosis (moderate or severe) * Known coronary artery disease * Left ventricular systolic dysfunction (ejection fraction \< 50%) * Recent septal reduction procedure (ie, surgical myectomy or alcohol septal ablation) within six months prior to screening or such a procedure scheduled to occur during the study Note: Other protocol defined Inclusion/Exclusion criteria may apply.